周新, 张旻 . 中国支气管哮喘防治指南（2020年版）解读[J]. 诊断学理论与实践, 2021 , 20(02) : 138 -143 . DOI: 10.16150/j.1671-2870.2021.02.004
| [1] | 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(12):1023-1048. |
| [2] | 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(9):675-697. |
| [3] | Lin J, Wang W, Chen P, et al. Prevalence and risk factors of asthma in mainland China: the CARE study[J]. Respir Med, 2018, 137:48-54. |
| [4] | Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019, 394(10196):407-418. |
| [5] | Su N, Lin J, Chen P, et al. Evaluation of asthma control and patient’s perception of asthma: findings and analysis of a nationwide questionnaire-based survey in China[J]. J Asthma, 2013, 50(8):861-870. |
| [6] | 林江涛, 王文巧, 周新, 等. 我国30个省市城区门诊支气管哮喘患者控制水平的调查结果[J]. 中华结核和呼吸杂志, 2017, 40(7):494-498. |
| [7] | 中华医学会变态反应分会呼吸过敏学组(筹), 中华医学会呼吸病学分会哮喘学组. 中国过敏性哮喘诊治指南(第一版,2019年)[J]. 中华内科杂志, 2019, 58(9):636-655. |
| [8] | 中华医学会呼吸病学分会哮喘学组, 中国哮喘联盟. 重症哮喘诊断与处理中国专家共识[J]. 中华结核与呼吸杂志, 2017, 40(11):813-829. |
| [9] | Sheikh A. Diagnosis and management of difficult-to-treat and severe asthma in adolescent and adult patients[R/OL]. [2021-02-20]. http://www.ginasthma.org/local/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1. |
| [10] | Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review[J]. Chest, 2011, 139(1):28-35. |
| [11] | Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial[J]. Lancet Respir Med, 2017, 5(5):390-400. |
| [12] | Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study[J]. Chest, 2016, 150(4):789-798. |
| [13] | FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10056):2128-2141. |
| [14] | Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. N Engl J Med, 2018, 378(26):2486-2496. |
| [15] | Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline[J]. Eur Respir J, 2020, 55(1):1900588. |
| [16] | 农英, 苏楠, 林江涛, 等. 支气管热成形术治疗重度支气管哮喘的有效性和安全性研究[J]. 中华结核与呼吸杂志, 2016, 39(3):177-182. |
/
| 〈 |
|
〉 |
